The modulation of DNMTs via approved DNMT inhibitors, such as 5-azacytidine and 2ʹ-deoxy-5-azacytidine [69,70], could also be a promising cancer epigenome-targeting strategy for cancer treatment. The gene discussed is DNMT1; the disease is cancer.